ArticleCurrent treatment options in oncology2013
Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.
Article in Current treatment options in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.American journal of clinical dermatology · 2024Trial
- Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.Journal for immunotherapy of cancer · 2021Trial
- Clinical characteristics and immunotherapy in Chinese patients with Merkel cell carcinoma: a retrospective analysis.Frontiers in oncology · 2026Article
- IGF2BP3 As a Prognostic Biomarker and Regulator of Metastasis in Merkel Cell Carcinoma.JID innovations : skin science from molecules to population health · 2025Article
- Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.International journal of molecular sciences · 2024Review
- Article
- The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.Journal of cancer research and clinical oncology · 2021Article
- Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.Future oncology (London, England) · 2020Article
- Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance.Cancer medicine · 2020Observational
- Cancer-testis antigens as biomarkers for Merkel cell carcinoma: Pitfalls and opportunities.Journal of cutaneous pathology · 2019Article
- The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA.Applied health economics and health policy · 2019Article
- Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.Molecules (Basel, Switzerland) · 2019Review
- Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer.Frontiers in medicine · 2019Review
- Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US.ClinicoEconomics and outcomes research : CEOR · 2019Article
- Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.The American journal of case reports · 2018Article
- Tumor cell death after electrotransfer of plasmid DNA is associated with cytosolic DNA sensor upregulation.Oncotarget · 2018Article
- Merkel Cell Polyomavirus Small T Antigen Drives Cell Motility via Rho-GTPase-Induced Filopodium Formation.Journal of virology · 2018Article
- Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?International journal of particle therapy · 2018Article
- Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.Annals of surgical oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer with a disease-specific mortality of approximately 40 %. The association of MCC with a recently discovered polyomavirus, combined with the increased incidence and mortality of MCC among immunocompromised patients, highlight the importance of the immune system in controlling this cancer. Initial management of MCC is summarized within the NCCN guidelines and in recently published reviews. The high rate of recurrent and metastatic disease progression in MCC, however, presents a major challenge in a cancer that lacks mechanism-based, disease-specific therapies. Traditional treatment approaches have focused on cytotoxic chemotherapy that, despite frequent initial efficacy, rarely provides durable responses and has high morbidity among the elderly. In addition, the immunosuppressive nature of chemotherapy is of concern when treating a virus-associated cancer for which survival is unusually tightly linked to immune function. With a median survival of 9.6 months after development of an initial metastasis (n = 179, described herein), and no FDA-approved agents for this cancer, there is an urgent need for more effective treatments. We review diverse management options for patients with advanced MCC, with a focus on emerging and mechanism-based therapies, some of which specifically target persistently expressed viral antigens. These treatments include single-dose radiation and novel immunotherapies, some of which are in clinical trials. Due to their encouraging efficacy, low toxicity, and lack of immune suppression, these therapies may offer viable alternatives to traditional cytotoxic chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.